| Outcome | Number of studies | Number of participants | Odds ratio [Confidence Interval] | -value |
| Serious adverse events with Tofacitinib 5 mg versus placebo at month 0–3 | 5 [15–19] | 1891 | 0.80 [0.47, 1.35] | 0.39 | Serious adverse events with Tofacitinib 10 mg versus placebo at month 0–3 | 5 [15–19] | 1896 | 0.77 [0.45, 1.31] | 0.33 | Serious infections with Tofacitinib 5 mg versus placebo at month 0–3 | 4 [15, 16, 18, 19] | 1423 | 1.91 [0.31, 11.70] | 0.49 | Serious infections with Tofacitinib 10 mg versus placebo at month 0–3 | 4 [15, 16, 18, 19] | 1418 | 2.10 [0.44, 9.94] | 0.35 | Serious adverse events with Tofacitinib 5 mg versus 10 mg at month 3–6 | 5 [15–19] | 2427 | 1.28 [0.80, 2.03] | 0.30 | Serious adverse events with Tofacitinib 5 mg versus 10 mg at month 6–12 | 2 [18, 19] | 1042 | 1.53 [0.79, 2.97] | 0.21 | Serious infections with Tofacitinib 5 mg versus 10 mg at month 3–6 | 4 [15, 16, 18, 19] | 1797 | 1.62 [0.67, 3.94] | 0.28 | Serious infections with Tofacitinib 5 mg versus 10 mg at month 6–12 | 2 [18, 19] | 1042 | 0.74 [0.16, 3.31] | 0.69 | Mild neutropenia (1500–1999 cells/mm3) with Tofacitinib 5 mg versus placebo at month 0–3 | 4 [15, 16, 18, 19] | 1308 | 1.55 [0.64, 3.77] | 0.33 | Mild neutropenia (1500–1999 cells/mm3) with Tofacitinib 10 mg versus placebo at month 0–3 | 4 [15, 16, 18, 19] | 1312 | 1.97 [0.83, 4.67] | 0.12 | Moderate to severe neutropenia (500–1499 cells/mm3) with Tofacitinib 5 mg versus placebo at month 0–3 | 4 [15, 16, 18, 19] | 1308 | 3.26 [0.71, 14.95] | 0.13 | Moderate to severe neutropenia (500–1499 cells/mm3) with Tofacitinib 10 mg versus placebo at month 0–3 | 4 [15, 16, 18, 19] | 1312 | 2.99 [0.52, 17.02] | 0.22 | Anaemia (decreased haemoglobin −1 to −3 g/dL) with Tofacitinib 5 mg versus placebo at month 0–3 | 4 [15, 16, 18, 19] | 1339 | 0.56 [0.38, 0.83] | 0.004* | Anaemia (decreased haemoglobin −1 to −3 g/dL) with Tofacitinib 10 mg versus placebo at month 0–3 | 4 [15, 16, 18, 19] | 1337 | 1.05 [0.74, 1.48] | 0.80 |
|
|